Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period - Concepedia

Concepedia

Publication | Open Access

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

DOI Full Paper Access

153

Citations

22

References

2020

Year

Francis Bérenbaum, Francisco J. Blanco, Ali Guermazi, Kenji Miki, Takaharu Yamabe, Lars Viktrup, Rod Junor, William Carey, Mark T. Brown, Christine R. West,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1